AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Latest quote
$36.18
+$0.14 · +0.39%
After-hours
$36.18
$0.00 · 0.00%
Oct 8, 4:43 PM ET
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
73
Undervalued
Sentiment
63
Bullish
Risk
44
Elevated Risk
Momentum
74
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Day range
Current $36.18
52-week range
Current $36.18
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 225.21M USD | 187.34M USD | 159.01M USD | 138.58M USD | 127.36M USD |
| Cost of goods sold | 57.86M USD | 45.36M USD | 37.14M USD | 29.78M USD | 22.93M USD |
| Gross profit | 167.35M USD | 141.98M USD | 121.87M USD | 108.81M USD | 104.43M USD |
| Research and development | 32.89M USD | 27.77M USD | 27.34M USD | 25.63M USD | 24.18M USD |
| Selling, general, and administrative | 142.32M USD | 117.5M USD | 115.99M USD | 112.89M USD | 105.67M USD |
| Operating expenses | 175.2M USD | 145.26M USD | 143.33M USD | 138.52M USD | 129.84M USD |
| Interest expense | 7.7M USD | 8.21M USD | 2.84M USD | 624K USD | 1.36M USD |
| Depreciation and amortization | 8.19M USD | 7.84M USD | 5.55M USD | 4.85M USD | 4.74M USD |
| Operating income | −7.85M USD | −3.29M USD | −21.46M USD | −29.71M USD | −25.42M USD |
| Net income | −15.7M USD | −9.96M USD | −21.72M USD | −28.95M USD | −26.99M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$53.17
46.96% upsideCash distributions grouped by calendar year; partial years are marked.
$1.00
2010 complete year+2296.8% since 1992
$0.0417
1,992
$0.06
2,005
$1.00
2,010
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jan 27, 2010 | $1.00Special | Jan 29, 2010 | Feb 12, 2010 |
Dividend | Feb 23, 2005 | $0.06Special | — | — |
Dividend | Jul 10, 1992 | $0.0417Special | — | — |
Ex-dividend Jan 27, 2010
$1.00
Special
Record Jan 29, 2010 · Payment Feb 12, 2010
Ex-dividend Feb 23, 2005
$0.06
Special
Ex-dividend Jul 10, 1992
$0.0417
Special
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI81.24M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM50.47M0.06%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF31.38M0.03%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO17.83M0.13%14.25B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO15.36M0.08%18B USD0.06%$112.1-0.10%
Schwab U.S. Small-Cap ETFSCHA11.15M0.05%21.7B USD0.03%$32.66+0.15%
Fidelity Enhanced Small Cap ETFFESM10.98M0.17%6.41B USD0.28%$45.25+0.07%
iShares U.S. Medical Devices ETFIHI10.49M0.30%3.5B USD0.37%$51.10+0.29%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
Fidelity Enhanced Small Cap ETFFESM
iShares U.S. Medical Devices ETFIHIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.